Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
de Bono, JS
MetadataShow full item record
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.
Version of record
Medicinal Chemistry 1 (including Analytical Chemistry)
Prostate Cancer Targeted Therapy Group
License start date
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 22 (17), pp. 4280 - 4282